GLP-1 drugs 2026 reached a turning point as the ADA's 86th Scientific Sessions closed in New Orleans on June 8 with Phase 3 results for retatrutide, orforglipron, CagriSema, and evolocumab — and a formal revision to ADA Standards of Care that now requires cardiovascular and kidney risk reduction as co-primary treatment goals alongside blood sugar control.